Gilead Sciences Inc , the world's largest maker of HIV drugs, said it received a subpoena for documents related to its manufacturing and quality and distribution practices.
News of the subpoena, from the United States Attorney's Office for the Northern District of California, sent the drugmaker's shares down 2.4 percent to $39.25.
The request applies to AIDS drugs Atripla, Emtriva, Truvada and Viread, hepatitis drug Hepsera, pulmonary hypertension drug Leitairis and Gilead's experimental fixed-dose combination of Truvada and Edurant.
Gilead said it is cooperating in the civil and criminal investigation.
© 2017 Thomson/Reuters. All rights reserved.